Toxicokinetics Data Summary

Route: Intravenous, Gavage

**Species/Strain:** Mouse/B6C3F1

Compound: Isoeugenol/ Analyte: Isoeugenol CAS Number: 97-54-1 Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Northwest Laboratory

#### Male

### Treatment Group (mg/kg)

35 IV Plasma<sup>a,c</sup> 35 G

35 Gavage Plasma<sup>b</sup> 70 Gavage Plasma<sup>b</sup>

140 Gavage Plasma<sup>b</sup>

| C_0min_pred (ug/mL)                                    | 17.1 ± 3.0      |                 |             |                 |
|--|-----------------|-----------------|-------------|-----------------|
| Cmax_obs (ug/mL)                                       |                 | $1.13 \pm 0.18$ | 1.27 ± 0.13 | $1.91 \pm 0.14$ |
| Tmax_obs (min)   |                 | 20              | 10          | 20              |
| Alpha (min <sup>-1</sup> )                             | 0.0872 ± 0.0068 |                 |             |                 |
| Alpha Half-life (min)                                  | 7.95 ± 0.62     |                 |             |                 |
| Beta (min <sup>-1</sup> )                              | 0.00587 ± 00162 |                 |             |                 |
| Beta Half-life (min <sup>-1</sup> )                    | 118 ± 33        |                 |             |                 |
| Cl (mLmin <sup>-1</sup> kg <sup>-1</sup> )             | 148 ± 5         |                 |             |                 |
| Cl1_F (mL*min* mLmin <sup>-</sup> 1*kg <sup>-1</sup> ) |                 | 522 ± 24        | 595 ± 26    | 690 ± 50        |
| V1 (L/kg)  | 25.2 ± 7.0      |                 |             |                 |
| AUC_0-T (ug mL <sup>-1</sup> min)                      | 197 ± 6         | $67.0 \pm 3.1$  | 118 ± 5     | 203 ± 15        |
| AUCinf_pred (ug mL <sup>-1</sup> min)                  | 208 ± 23        |                 |             |                 |
| F (percent)  |                 | 34 ± 4          |             |                 |

| Experiment Number: K10262    | Toxicokinetics Data Summary               | Request Date: 7/11/2023            |
|------------------------------|---|------------------------------------|
| Route: Intravenous, Gavage   | Compound: Isoeugenol/ Analyte: Isoeugenol | Request Time: 10:03:16             |
| Species/Strain: Mouse/B6C3F1 | <b>CAS Number:</b> 97-54-1                | Lab: Battelle Northwest Laboratory |

## **Lab:** Battelle Northwest Laboratory

#### Female

# Treatment Group (mg/kg)

35 IV Plasma<sup>a,c</sup>

35 Gavage Plasma<sup>b</sup>

70 Gavage Plasma<sup>b</sup> 140 Gavage Plasma<sup>b</sup>

| C_0min_pred (ug/mL)                                    | 18.0 ± 2.5        |             |             |             |
|--|-------------------|-------------|-------------|-------------|
| Cmax_obs (ug/mL)                                       |                   | 1.94 ± 0.17 | 2.54 ± 0.17 | 3.99 ± 2.10 |
| Tmax_obs (min)   |                   | 10          | 20          | 5           |
| Alpha (min <sup>-1</sup> )                             | 0.0666 ± 0.0045   |             |             |             |
| Alpha Half-life (min)                                  | 10.4 ± 0.7        |             |             |             |
| Beta (min <sup>-1</sup> )                              | 0.00679 ± 0.00131 |             |             |             |
| Beta Half-life (min <sup>-1</sup> )                    | 102 ± 20          |             |             |             |
| Cl (mLmin <sup>-1</sup> kg <sup>-1</sup> )             |                   | 108 ± 2     |             |             |
| Cl1_F (mL*min* mLmin <sup>-</sup> 1*kg <sup>-1</sup> ) |                   | 348 ± 14    | 338 ± 18    | 350 ± 31    |
| V1 (L/kg)  | 16.0 ± 3.1        |             |             |             |
| AUC_0-T (ug mL <sup>-1</sup> min)                      | 278 ± 3           | 101 ± 4     | 207 ± 11    | 400 ± 36    |
| AUCinf_pred (ug mL <sup>-1</sup> min)                  | 284 ± 25          |             |             |             |
| F (percent)  |                   | 36 ± 3      |             |             |

LEGEND

MODELING SOFTWARE PROC NLIN

#### MODELING METHOD & BEST FIT MODEL

<sup>a</sup>A nonlinear least-squares fitting program SAS PROC NLIN, SAS Institute, Inc., Cary, NC. Elimination of IEG was modeled for both species using a biphasic exponential equation  $C(t) = Aoe^{-alpha^*t} + Boe^{-beta^*t}$  () where C(t) is the plasma IEG concentration at any post-administration time (t), alpha and beta are the rate constants (min-1) obtained from the fit, Ao and Bo are the intercepts on the ordinate (concentration) axis of the extrapolated initial and terminal phases, respectively. weighting factor of [mean plasma IEG concentration]-2.

<sup>b</sup>Manual, Plasma MEG concentration-versus-time profiles for both species were characterized by an early absorption phase followed by at least one secondary peak which prevented estimation of elimination rates. No modeling was done on the oral gavage data. Parameters were calculated using observed values.

#### EXCEPTIONS

<sup>c</sup>Cl is total clearance, V2 represent Vapp

#### ANALYTE

Isoeugenol

#### TK PARAMETERS

C\_Omin\_pred = Fitted plasma concentration at time zero (IV only)

Cmax\_obs = Observed or Predicted Maximum plasma (or tissue) concentration

Tmax\_obs = Time at which Cmax predicted or observed occurs

Alpha = Hybrid rate constant of the alpha phase

Alpha Half-life = Half-life of the alpha phase

Beta = Hybrid rate constant of the beta phase

Beta Half-life = Half-life of the beta phase

### TK PARAMETERS (cont'd)

- CI = Clearance, includes total clearance
- Cl1\_F = Apparent clearance of the central compartment, also Cl\_F for gavage groups in non-compartmental model
- V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA, Vapp apparent volume of distribution for intravenous studies
- AUC\_0-T = Area under the plasma concentration versus time curve, AUC, from time ti (initial) to tf (final), AUClast
- AUCinf\_pred = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity
- F = Bioavailability, absolute bioavailability

### TK PARAMETERS PROTOCOL

### ANALYSIS METHOD

Plasma Isoeugenol (IEG) concentrations were measured using a validated gas chromatography-mass spectrometry (GC-MS) method. Plasma level of detection (LOD) is 0.0009 ug/mL, the limit of quantitation (LOQ) is 0.0031 ug/mL and the plasma experimental level of detection ELOQ is 0.015 ug/mL. All IV dosed mice IEG concentrations were above the LOD and only 14 out of 83 measurements fell between the LOD and the ELOQ.

### TK\_INTRAVENOUS PLASMA

### 35 mg/kg Male and Female

Animals were weighed the morning of dosing for calculation of the dosing volume. Non-fasted mice were given a single bolus intravenous injection through a Silastic catheter surgically implanted by the supplier followed by approximately 0.2 mL of heparinized saline solution (10 units/mL). Three mice/sex were bled at each time point with the exception of the last time point for males where only two animals were available for bleeding. Each mouse was bled only once and the maximum amount of blood was collected via a closed chest cardiac puncture. 14 time points. Animals were anesthetized with approximately 70 percent CO2-30 percent O2.

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Northwest Laboratory

### TK PARAMETERS PROTOCOL (cont'd)

TK\_GAVAGE PLASMA

#### 35 mg/kg, 70 mg/kg, 140 mg/kg Male and Female

Animals were weighed the day prior to dosing for calculation of the dosing volume and given a single gavage dose the next morning. Three mice/sex were bled at each time point with the exception of the last time point for males where only two animals were available for bleeding. Each mouse was bled only once and the maximum amount of blood was collected via a closed chest cardiac puncture. 14 time points. Animals were anesthetized with approximately 70 percent CO2-30 percent O2.